TY  - GEN 
AU  - Isla, D.
AU  - Massuti, B.
AU  - Lazaro Quintela, Martín
AU  - de Alda, L. R.
AU  - Gordo, R.
AU  - Ortega-Joaquín, N.
AU  - Oyagüez, I.
PY  - 2020
SN  - 1758-1966
UR  - http://hdl.handle.net/20.500.11940/16817
AB  - Aim: To estimate management cost of NSCLC ALK+ patients with and without brain metastasis (BM), and to compare annual costs in patients treated with alectinib or crizotinib. Methods: Management cost/year (euro 2018) in patients with and without BM was...
TI  - Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
DO  - 10.2217/lmt-2019-0011
KW  - CHUVI
VL  - 9
ER  -